may differ materially from these forward-looking statements because of Human Genome Sciences' unproven business model, its dependence on new technologies, the uncertainty and timing of clinical trials, Human Genome Sciences' ability to develop and commercialize products, its dependence on collaborators for services and revenue, its substantial indebtedness and lease obligations, its changing requirements and costs associated with facilities, intense competition, the uncertainty of patent and intellectual property protection, Human Genome Sciences' dependence on key management and key suppliers, the uncertainty of regulation of products, the impact of future alliances or transactions and other risks described in the Company's filings with the SEC. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. Human Genome Sciences undertakes no obligation to update or revise the information contained in this announcement whether as a result of new information, future events or circumstances or otherwise.
'/>"/>SOURCE Human Genome Sciences, Inc. Copyright©2009 PR Newswire. All rights reserved | |
Page: 1 2 3 Related biology technology :1.
Expiry of Hart-Scott-Rodino Waiting Period for JUVISTA(R) (Human TGF BETA 3)2.
New Initiative Has Shocking Effect: Thousands of Missourians with Abnormal Chromosome Structures Are Not Human3.
ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials4.
Human Genome Sciences Announces $40 Million Milestone Payment Related to Albuferon(R) Development5.
Novocell Announces Discovery Linking Key Cancer Cell Signaling Pathways With Proliferation and Self-Renewal of Human Embryonic Stem Cells6.
Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Thomas Weisel Partners Conference7.
Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at BioCentury-Thomson Financial Investment Conference8.
Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Bear Stearns Conference9.
Human Pheromone Sciences Enters Into Agreement to Reposition and Promote its Natural Attraction(R) Brand10.
Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Merrill Lynch Conference11.
Premier Research Appoints Global Head of Human Resources